147 related articles for article (PubMed ID: 38411250)
1. Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.
Mosquera Orgueira A; Perez Encinas MM; Diaz Varela N; Wang YH; Mora E; Diaz-Beya M; Montoro MJ; Pomares Marin H; Ramos Ortega F; Tormo M; Jerez A; Nomdedeu J; de Miguel Sanchez C; Arenillas L; Carcel P; Cedena Romero MT; Xicoy Cirici B; Rivero Arango E; Del Orbe Barreto RA; Benlloch L; Lin CC; Tien HF; Pérez Míguez C; Crucitti D; Díez Campelo M; Valcárcel D
Br J Haematol; 2024 Apr; 204(4):1529-1535. PubMed ID: 38411250
[TBL] [Abstract][Full Text] [Related]
2. Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes.
Mosquera Orgueira A; Perez Encinas MM; Diaz Varela NA; Mora E; Díaz-Beyá M; Montoro MJ; Pomares H; Ramos F; Tormo M; Jerez A; Nomdedeu JF; De Miguel Sanchez C; Leonor A; Cárcel P; Cedena Romero MT; Xicoy B; Rivero E; Del Orbe Barreto RA; Diez-Campelo M; Benlloch LE; Crucitti D; Valcárcel D
Hemasphere; 2023 Oct; 7(10):e961. PubMed ID: 37841754
[TBL] [Abstract][Full Text] [Related]
3. A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia.
Wang YH; Yao CY; Lin CC; Gurashi K; Amaral FMR; Bossenbroek H; Jerez A; Somervaille TCP; Binder M; Patnaik MM; Hou HA; Chou WC; Batta K; Wiseman DH; Tien HF
Br J Haematol; 2023 Apr; 201(2):302-307. PubMed ID: 36746431
[TBL] [Abstract][Full Text] [Related]
4. Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.
Moreno Berggren D; Kjellander M; Backlund E; Engvall M; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ungerstedt J; Ejerblad E
Br J Haematol; 2021 Feb; 192(3):474-483. PubMed ID: 32501529
[TBL] [Abstract][Full Text] [Related]
5. Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.
Triguero A; Xicoy B; Zamora L; Jiménez MJ; García O; Calabuig M; Díaz-Beyá M; Arzuaga J; Ramos F; Medina A; Bernal T; Talarn C; Coll R; Collado R; Chen TH; Borrás J; Brunet S; Marchante I; Marco V; López-Cadenas F; Calbacho M; Simiele A; Cortés M; Cedena MT; Pedreño M; Aguilar C; Pedró C; Fernández M; Stoica C; Ribera JM; Sanz G
Leuk Res; 2022 May; 116():106836. PubMed ID: 35405632
[TBL] [Abstract][Full Text] [Related]
6. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
7. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.
Padron E; Steensma DP
Curr Opin Hematol; 2015 Mar; 22(2):163-70. PubMed ID: 25575034
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.
Such E; Germing U; Malcovati L; Cervera J; Kuendgen A; Della Porta MG; Nomdedeu B; Arenillas L; Luño E; Xicoy B; Amigo ML; Valcarcel D; Nachtkamp K; Ambaglio I; Hildebrandt B; Lorenzo I; Cazzola M; Sanz G
Blood; 2013 Apr; 121(15):3005-15. PubMed ID: 23372164
[TBL] [Abstract][Full Text] [Related]
9. Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS).
Kasprzak A; Nachtkamp K; Gattermann N; Germing U
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454847
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.
Pleyer L; Leisch M; Kourakli A; Padron E; Maciejewski JP; Xicoy Cirici B; Kaivers J; Ungerstedt J; Heibl S; Patiou P; Hunter AM; Mora E; Geissler K; Dimou M; Jimenez Lorenzo MJ; Melchardt T; Egle A; Viniou AN; Patel BJ; Arnan M; Valent P; Roubakis C; Bernal Del Castillo T; Galanopoulos A; Calabuig Muñoz M; Bonadies N; Medina de Almeida A; Cermak J; Jerez A; Montoro MJ; Cortés A; Avendaño Pita A; Lopez Andrade B; Hellstroem-Lindberg E; Germing U; Sekeres MA; List AF; Symeonidis A; Sanz GF; Larcher-Senn J; Greil R
Lancet Haematol; 2021 Feb; 8(2):e135-e148. PubMed ID: 33513373
[TBL] [Abstract][Full Text] [Related]
11. Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study.
Roupie AL; Guedon A; Terrier B; Lahuna C; Jachiet V; Regent A; de Boysson H; Carrat F; Seguier J; Terriou L; Versini M; Queyrel V; Groh M; Benhamou Y; Maurier F; Ledoult E; Clech LL; D'Aveni M; Rossignol J; Galland J; Willems L; Chiche NJ; Peterlin P; Roux-Sauvat M; Parcelier A; Wemeau M; Lambert M; Belizna C; Puechal X; Swiader L; Cohen-Valensi R; Noc V; Dao E; Thepot S; de Frémont GM; Tanguy-Schmidt A; Koka AM; Bussone G; Philipponnet C; Konate A; Cavaille G; Guilpain P; Allain JS; Broner J; Solary E; Ruivard M; de Renzis B; Corm S; Baati N; Schleinitz N; Ponsoye M; Stamatoullas-Bastard A; Ades L; Dellal A; Tchirkov A; Aouba A; Fenaux P; Fain O; Mekinian A;
Semin Arthritis Rheum; 2020 Oct; 50(5):879-884. PubMed ID: 32896704
[TBL] [Abstract][Full Text] [Related]
12. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
13. PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.
Chamseddine AN; Cabrero M; Wei Y; Ganan-Gomez I; Colla S; Takahashi K; Yang H; Bohannan ZS; Garcia-Manero G
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S67-73. PubMed ID: 27521329
[TBL] [Abstract][Full Text] [Related]
14. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
[TBL] [Abstract][Full Text] [Related]
15. Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes.
Aguirre LE; Al Ali N; Sallman DA; Ball S; Jain AG; Chan O; Tinsley-Vance SM; Kuykendall A; Sweet K; Lancet JE; Padron E; Komrokji RS
Leukemia; 2023 Jul; 37(7):1530-1539. PubMed ID: 37147425
[TBL] [Abstract][Full Text] [Related]
16. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
[TBL] [Abstract][Full Text] [Related]
17. Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale.
Ramadan H; Duong VH; Al Ali N; Padron E; Zhang L; Lancet JE; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S64-6. PubMed ID: 27521328
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
[TBL] [Abstract][Full Text] [Related]
19. Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.
Wall M
Methods Mol Biol; 2017; 1541():209-222. PubMed ID: 27910026
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes.
Nomdedeu M; Calvo X; Pereira A; Carrió A; Solé F; Luño E; Cervera J; Vallespí T; Muñoz C; Gómez C; Arias A; Such E; Sanz G; Grau J; Insunza A; Calasanz MJ; Ardanaz MT; Hernández-Rivas JM; Azaceta G; Álvarez S; Sánchez J; Martín ML; Bargay J; Gómez V; Cervero CJ; Allegue MJ; Collado R; Campo E; Esteve J; Nomdedeu B; Costa D;
Genes Chromosomes Cancer; 2016 Apr; 55(4):322-7. PubMed ID: 26690722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
